‘Boomerang’ cancer therapy from Ben-Gurion University wins medical category in iGEM competition

BOSTON…September 30, 2015 – The student team from Ben-Gurion University of the Negev has just won the Best Heath and Medicine Project category in the prestigious 12th annual iGEM 2015 Giant Jamboree (International Genetically Engineered Machine) competition with their cutting-edge biological cancer therapy called “Boomerang.”

The winners were announced at the Awards Gala on Monday, September 28 at the Hynes Auditorium in Boston. IGEM is considered one of the most important ventures in the global sphere of science. Nearly 4,600 students competed in this year’s event held from September 24-28. Their local experiences in a global community impart unique perspective in the field, especially as projects span a broad range across 15 different tracks — including health and medicine, energy, environment, food and nutrition, manufacturing, and others.

The BGU project Boomerang is based on advanced methods of genetic engineering and synthetic biology. It has many applications that rely on the special characteristics of cancer cells to identify and alter cells as well as treat the disease at the molecular level. As a cancer therapy, Boomerang works as a modular system, which recognizes cancer cells at a high level of specificity. It can cause disruption of genes essential for cancer survival or activate suicide genes so that the cancer or tumor kills itself. Boomerang can also produce color proteins for cancer cell detection so that the edges of a tumor are visible to ensure complete surgical removal. The name “Boomerang” mirrors the actions in which the synthetic system uses cancer cells’ own genetic alterations against them.

“Most treatments cannot distinguish precisely enough between cancer and healthy cells,” according to the BGU iGEM team website. “Low specificity means higher toxicity and high rate of adverse effects. The BGU Boomerang system can be potentially designed according to unique characteristics of a patient’s tumor, paving the way to personalized medicine. We believe our strategy demonstrated in the winning prototype/proof-of-concept studies can change the approach to cancer treatments.”

In addition to winning the grand prize in the Best Health and Medicine Project in the “Overgraduate” category (graduate level), the BGU team was a first runner-up in the overall competition, the first Israeli team to reach this level in iGEM. Lastly, the BGU team also won the Best New Basic Part Award for developing and submitting the best new functional DNA sequence to this year’s competition.

“The University is so proud to have succeeded in this prestigious competition, which includes the best and brightest students in the synthetic biology field,” says Prof. Smadar Cohen, team leader and a member of the BGU Avram and Stella Goldstein-Goren Department of Biotechnology Engineering.